Study protocol for the ABERRANT study: antibiotic-induced disruption of the maternal and infant microbiome and adverse health outcomes — a prospective cohort study among children born at term
Volery, MaryseFaculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland
Scherz, ValentinInstitute of Microbiology, Lausanne University Hospital, Lausanne, Switzerland - Facultiy of Medicine, University of Lausanne, Lausanne, Switzerland
Lauber-Biason, AnnaFaculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland
Wildhaber, JohannesFaculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland
Falquet, LaurentDepartment of Biology, University of Fribourg, Fribourg, Switzerland - Swiss Institute of Bioinformatics, Lausanne, Switzerland
Curtis, NigelDepartment of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia - Infectious Diseases Research Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia - Infectious Diseases Unit, The Royal Children’s Hospital Melbourne, Parkville, Victoria, Australia
Zimmermann, PetraFaculty of Science and Medicine, University of Fribourg, Fribourg, Switzerland - Department of Paediatrics, Fribourg Hospital HFR, Fribourg, Switzerland - Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia - Infectious Diseases Research Group, Murdoch Children’s Research Institute, Parkville, Victoria, Australia
English
Introduction: There is compositional overlap between the maternal intestinal microbiome, the breast milk microbiome and the infant oral and intestinal microbiome. Antibiotics cause profound changes in the microbiome. However, the effect of intrapartum and early-life antibiotics on the maternal intestinal and breast milk microbiome, and the infant oral and intestinal microbiome, and whether effects are only short term or persist long term remain uncertain. Methods and analyses: In this prospective cohort study, we will use metagenomic sequencing to determine: (1) the effect of intrapartum antibiotics on the composition of the breast milk, and the infant oral and intestinal microbiome, including the development and persistence of antibiotic resistance; (2) the effect of antibiotic exposure in the first year of life on the composition of the infant oral and intestinal microbiome, including the development and persistence of antibiotic resistance; (3) the effect of disruption of the infant oral and intestinal microbiome on health outcomes and (4) the compositional overlap between the maternal intestinal microbiome, the breast milk microbiome and the infant oral and intestinal microbiome. Ethics and dissemination: The ABERRANT study has been approved by the commission cantonale d’éthique de la recherche sur l’être humain (CER-VD) du Canton de Vaud (#2019–01567). Outcomes will be disseminated through publication and will be presented at scientific conferences. Trial registration number NCT04091282.